GLP-1受体激动剂的临床研究进展

发布时间：2018-05-15 04:05

  本文选题：型糖尿病 + GLP-受体激动剂　； 参考：《中国新药杂志》2015年19期

【摘要】：当前研究已经显示2型糖尿病同肥胖症具有并发趋势,临床上也公认将控制患者体重列入到2型糖尿病治疗指南中。目前在已经过验证的治疗方案中,只有胰高血糖素样肽受体激动剂(glucagon-like peptide-1 receptor agonists,GLP-1 RAs)可以实现对患者的体重和血糖水平同时调控。GLP-1作为GLP-1受体激动剂研究的基础,具有血糖依赖性的促进胰岛素分泌作用。其可以通过抑制食欲和减缓胃排空来达到减轻体重的作用。天然的GLP-1由于受到二肽基肽酶(dipeptide peptidase,DPP-Ⅳ)的降解作用,半衰期仅为2 min。为了延长GLP-1 RAs的体内半衰期,多种改造策略被应用于新型GLP-1受体激动剂的研究开发,目前此类GLP-1受体激动剂已部分进入临床评估阶段,给药频率将从每周1次延长到每月1次。本文将对近年来已进入临床试验研究的GLP-1受体激动剂进行综述。
[Abstract]:Current studies have shown that type 2 diabetes has a tendency to be associated with obesity, and it is also recognized that weight control is included in the treatment guidelines for type 2 diabetes. At present, only glucagon-like peptide-1 receptor agonists, glucagon-like peptide-1 receptor agonistsGLP-1 RAsS, have been proven to be the basis for simultaneous regulation of body weight and blood glucose levels as GLP-1 receptor agonists. Promote insulin secretion in a glucose dependent manner. It can reduce weight by suppressing appetite and reducing gastric emptying. The natural GLP-1 was degraded by dipeptidyl peptidase (DPP- 鈪，

本文编号：1890874